Clinical recommendations for the prostate-specific antigen in the spanish autonomous communities and cities Section: Originals How to quote Cañabate Blanco M, Álvarez Dardet C, Marcos Marcos J. Recomendaciones clínicas del antígeno prostático específico en las CC.AA. y ciudades autónomas españolas. RIdEC 2022; 15(1):45-53. AuthorsMarina Cañabate Blanco, Carlos Álvarez Dardet, Jorge Marcos Marcos Position 1 Enfermera.2 Grupo de investigación en Salud Pública. Universidad de Alicante. España.3 Dr. Departamento de Psicología de la Salud. Universidad de Alicante. España. Contact email: marinaalamoblanco@gmail.com Abstract Objective: to review the clinical practice recommendations available in Spain regarding prostate cancer screening, assessing their suitability according to the indications by the U.S Preventive Services Task Force.Methods: a review of the clinical practice recommendations for prostate cancer screening by the main scientific societies and the health authorities of the autonomous communities. A subsequent comparison with the U.S Preventive Services Task Force.Results: both the Regional Ministries of Health of the autonomous communities and the scientific societies, except for two who showed ambiguity, have ruled out its routine use and implementation as a program for early detection.Conclusion: there are still recommendations for PSA testing in asymptomatic men. Keywords: Public Health; screening; prostate neoplasiaclinical practice guidelines as subject matter Versión en Español Título: Recomendaciones clínicas del antígeno prostático específico en las CC.AA. y ciudades autónomas españolas